GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Equity-to-Asset

Molecular Templates (Molecular Templates) Equity-to-Asset

: 0.12 (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Molecular Templates's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.21 Mil. Molecular Templates's Total Assets for the quarter that ended in Dec. 2023 was $35.38 Mil. Therefore, Molecular Templates's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.12.

The historical rank and industry rank for Molecular Templates's Equity-to-Asset or its related term are showing as below:

MTEM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35   Med: 0.51   Max: 0.86
Current: 0.12

During the past 13 years, the highest Equity to Asset Ratio of Molecular Templates was 0.86. The lowest was -0.35. And the median was 0.51.

MTEM's Equity-to-Asset is ranked worse than
81.61% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs MTEM: 0.12

Molecular Templates Equity-to-Asset Historical Data

The historical data trend for Molecular Templates's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.42 0.34 -0.16 0.12

Molecular Templates Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.02 -0.24 0.15 0.12

Competitive Comparison

For the Biotechnology subindustry, Molecular Templates's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Templates Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Molecular Templates's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Molecular Templates's Equity-to-Asset falls into.



Molecular Templates Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Molecular Templates's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.212/35.383
=0.12

Molecular Templates's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.212/35.383
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Templates  (NAS:MTEM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Molecular Templates Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Molecular Templates's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Templates (Molecular Templates) Business Description

Traded in Other Exchanges
N/A
Address
9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.
Executives
Maurizio Voi officer: Chief Medical Officer 4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan officer: CFO & Treasurer C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande director, 10 percent owner 201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc 10 percent owner FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim officer: See Remarks 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch director, 10 percent owner C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p. 10 percent owner 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein director C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019